
- Volume 0 0
Cancer Drug Also Helps Lupus and Arthritis
A recent study shows that the cancerdrug rituximab may benefit lupus patientswith central nervous system complications.Researchers claim that it is "a kinder,gentler form of treatment?with a low riskof side effects, compared to?high-dosesteroids and chemotherapy," the standardtreatments for the disease.
The 16-month study included 22patients with lupus. More than 50% weregiven rituximab alone, another group tookthe drug along with steroids, and a thirdgroup took it with the chemotherapyagent cyclophosphamide. Sixteen of thepatients showed significant improvementin their conditions. Brain scans showedimprovements in adverse effects causedby the disease.
Another study showed rituximab to beeffective in treating rheumatoid arthritisas well. This study included 465 men andwomen who had had arthritis for ~10years. The results of the 24-week studyshowed that 2 different doses of rituximabwere both effective in treating the disease,with the higher dose having thegreatest effect. Researchers found thatthe drug targets a specific type of immunecell and helps control inflammation andpain in arthritis patients.
Articles in this issue
about 20 years ago
A Pharmacist's Guide to OTC Therapy: Ocular Care Productsabout 20 years ago
Dangerous Liaisons: Schizophrenia and Diabetesabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Nutritional Supplementsabout 20 years ago
Tarceva Extends Lung Cancer Survivalabout 20 years ago
Inhaled Morphine Aids Cancer-related Dyspneaabout 20 years ago
Diuretic Best BP Therapy for African Americansabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Foot Care Productsabout 20 years ago
New Drug Blocks Out AIDS Virusabout 20 years ago
Viagra Ingredient Has Another Useabout 20 years ago
GUEST COMMENTARY: FIGHTING THE NEW PHARMACOPHOBIANewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.













































































































































































































